Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-CORE1201 bi-weekly cetuximab plus mFOLFOX6 or mFOLFIRI in KRAS wild-type unresectable colorectal cancer
jRCTs021180014Phase 2Completed
- Sponsor
- Tohoku Clinical Oncology Research and Educational Society
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab in colorectal cancer (CRC) (2 arms), sponsored by Tohoku Clinical Oncology Research and Educational Society. Primary endpoint: Median progression-free survival. Started Jun 2012; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs021180014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180014.